KPV: The Alpha-MSH Tripeptide With a 20-Year Preclinical Record Now Facing Its First Formal FDA Compounding Review

Key takeaways

• KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH), studied preclinically for intestinal inflammation, wound healing, and skin conditions since the early 2000s.
• Its mechanism centres on intracellular suppression of NF-κB and MAPK signalling pathways, apparently independent of melanocortin receptor activation.
• The evidence base spans over 50 peer-reviewed publications according to suppliers, but comprises almost entirely cell-culture and animal model data; no large-scale human clinical trials have been completed.
• KPV was placed on the FDA's Category 2 restricted compounding list in 2023, removed from that list in April 2026 after the original nominators withdrew their submissions, and is now scheduled for formal PCAC review on 23 July 2026.
• A positive PCAC recommendation would support KPV's inclusion on the 503A Bulk Drug Substances List — a necessary but not sufficient step toward legal compounding under physician prescription.
• KPV carries no approved indication in the US, UK, or EU. In the UK, it remains outside any MHRA-authorised framework and is currently available only as a research-use-only chemical.

What KPV is

KPV stands for lysine-proline-valine, the sequence of its three constituent amino acids. It is the C-terminal sequence (positions 11–13) of alpha-melanocyte-stimulating hormone (α-MSH), a neuropeptide produced in the pituitary gland. Alpha-MSH is a thirteen-residue melanocortin peptide, and within that sequence sits KPV — the minimal fragment that, in published preclinical work, retains much of the parent hormone's anti-inflammatory signalling while shedding the pigmentary activity that characterises the full melanocortin.

Chemically, KPV is H-Lys-Pro-Val-OH. Its simple backbone provides stability against some digestive enzymes, and its specific amino-acid sequence enables direct interaction with immune cells. It is one of the shortest peptides in active clinical research — just three amino acids long. Despite its size, researchers have studied it for decades as an anti-inflammatory compound with potential applications in wound healing, inflammatory bowel disease, and skin conditions.

Mechanism of action

The primary mechanistic interest in KPV lies in how it suppresses inflammation. KPV is derived from α-MSH and suppresses the NF-κB inflammatory pathway directly inside cells — without systemic immune suppression, without the side effects of steroids, and without melanocortin receptor activation. This intracellular route distinguishes it from many anti-inflammatory agents that act at surface receptors.

In preclinical models, KPV is reported to inhibit NF-κB and MAP-kinase signalling at nanomolar concentrations and to reduce pro-inflammatory cytokine output in intestinal and epithelial cells. A key facilitating factor is cellular uptake: a landmark 2008 study published in Gastroenterology demonstrated that KPV is transported into colonic cells via the PepT1 transporter and reduces DSS- and TNBS-induced colitis in mice. Oral KPV decreased pro-inflammatory cytokine expression and attenuated disease severity across multiple colitis models.

The PepT1 pathway is particularly relevant to the oral delivery research: because PepT1 is expressed in the intestinal epithelium, it provides a mechanism by which a short, orally administered peptide can enter cells and exert intracellular effects without being fully degraded in the gastrointestinal tract.

KPV modulates inflammation by downregulating pro-inflammatory cytokines such as TNF-α and IL-1β. More recent preclinical work has extended these observations: a 2025 study demonstrated that KPV mitigated fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Treatment with KPV restored cell viability and reduced IL-1β secretion.

The evidence base: strengths and limitations

The published literature on KPV is notably narrow in one critical respect. The body of KPV research consists almost entirely of preclinical studies using cell culture and animal models. No large-scale human clinical trials have been completed.

That said, the preclinical record is substantive. In addition to the IBD colitis models, a 2016 study in Cellular and Molecular Gastroenterology and Hepatology showed that KPV dramatically reduced colonic tumorigenesis in a mouse model of colitis-associated cancer, with tumour numbers, sizes, and overall burden decreased in KPV-treated animals — an effect abolished in PepT1-knockout mice, confirming PepT1 dependence.

On the dermatological side, wound healing involves inflammation, epithelial migration, collagen remodelling, infection control, blood supply, and tissue repair. KPV-related research has raised questions about epithelial injury and inflammatory signalling, but robust human evidence for wound healing outcomes is not established.

In preclinical antimicrobial work, a 2000 Journal of Leukocyte Biology study described KPV's effect on common pathogens including Staphylococcus aureus and Candida albicans, finding that even very small concentrations of the peptide reduced pathogen viability — and noting that, unlike many anti-inflammatory drugs, KPV did not decrease immune function.

Unlike corticosteroids, KPV does not appear to suppress immune function broadly. Long-term human safety data are not available. This gap — a deep preclinical record alongside an essentially absent human trial dataset — is precisely the concern the FDA cited when it placed the peptide in Category 2 in 2023, and it remains the central challenge before the July PCAC.

Regulatory history and current status

KPV's regulatory journey follows a pattern now familiar across the compounding peptide space. The FDA categorised more than a dozen peptides as Category 2 substances and deemed them unsafe for bulk compounding in 2023. The agency cited "significant safety concerns" for these popular peptides, including risks related to immunogenicity, impurities, and availability of only limited human clinical data.

KPV was placed on the FDA Category 2 restricted list in 2023, then removed on 22 April 2026 because nominators withdrew their submissions — which is not the same as approval. That procedural removal should not be read as a go-ahead to compound these peptides. Under the FDA's current policy, removal of a bulk drug substance from Category 2 does not, on its own, authorise use of that substance in compounding.

KPV is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on 23 July 2026. The committee will evaluate KPV for wound healing and inflammatory conditions and consider it for the Section 503A Bulk Drug Substances List.

What the PCAC process means in practice

The 23 July review is a necessary procedural step, not a final determination. The PCAC analysis typically considers four factors: the physical and chemical characterisation of the substance, any safety issues raised by using the substance in compounding, the available evidence of effectiveness for the use, and historical use of the substance in compounding.

Recommendations are non-binding. The FDA ultimately decides whether to add a substance to the list. But PCAC recommendations carry significant weight — a positive recommendation tends to move the process forward, while a negative one often means the substance stays off the list.

Even a positive recommendation does not immediately authorise compounding. Formal rulemaking is what follows PCAC's recommendation — a process that, under standard timelines, can take more than a year even if the FDA agrees with the committee.

It is also important to note that the current review is confined to the 503A pathway. The FDA has been silent concerning 503B outsourcing facilities' ability to compound using peptides — the agency has not indicated that these peptides will be reviewed for or otherwise moved to the separate 503B Category 1 list. For research procurement purposes, this distinction matters: 503A governs individual patient-specific compounding by licensed pharmacies, whilst 503B governs larger-scale outsourcing facilities.

The public comment docket (FDA-2025-N-6895) remains open through 22 July 2026. KPV is being reviewed specifically for wound healing and inflammatory conditions — the two areas best supported by existing preclinical data.

UK and European regulatory context

KPV carries no approved indication in the UK or the European Union. KPV has no FDA-, EMA-, or other approved formulation anywhere. In the UK, the MHRA has not issued any specific guidance on KPV. It sits outside the Medicines Act 1968 licensed framework and is available to UK research organisations strictly as a research-use-only (RUO) chemical reagent — a designation that restricts its use to in vitro and preclinical work and does not permit administration to humans outside an authorised clinical trial context.

Supplement-style oral and topical KPV products are sold under a different regulatory framework than compounded injectables in the US, which is why KPV capsules and patches are marketed directly to consumers. Quality and oversight in that channel vary widely. UK-based procurement teams sourcing KPV for legitimate laboratory use should verify that suppliers provide a Certificate of Analysis with mass spectrometry confirmation of identity and HPLC-verified purity, given the documented variability in unregulated supply channels.

Implications for research procurement

The July 2026 PCAC vote will serve as a useful signal for research planning, even though its direct regulatory effect in the UK is limited. A positive recommendation from a credible FDA advisory body would likely accelerate interest in KPV-focused research programmes globally, potentially affecting demand and pricing for research-grade material. A negative recommendation would harden the existing regulatory posture and may reduce commercial supplier support for the compound.

The July 2026 advisory review could reopen compounding pathways for peptides previously curtailed in 2023 over immunogenicity, toxicity, impurity risk, and inadequate human clinical evidence. However, even if the advisory panel votes in favour of these peptides, the subsequent rulemaking process will be a protracted one.

For UK laboratories, the more immediate consideration is the quality of preclinical-grade material. KPV's molecular simplicity — three amino acids, molecular weight 342.43 g/mol — means that synthesis and characterisation are relatively straightforward, but the short sequence also means that even minor impurities or sequence errors are proportionally significant. Lot-to-lot consistency checks, vendor audits, and mass spectrometry confirmation of the Lys-Pro-Val sequence remain standard due-diligence requirements before any in-house research programme is established.

This briefing is for research-procurement professionals. KPV is not approved for human use in the UK, US, or EU. Nothing in this article constitutes medical, legal, or regulatory advice.